康诺亚生物CM512获突破性疗法认定,用于慢性鼻窦炎伴鼻息肉治疗

美股速递
Jul 23

康诺亚生物旗下药物CM512,已被纳入针对慢性鼻窦炎伴鼻息肉(CRSwNP)的突破性疗法认定名单。这一认定标志着该候选疗法在满足未满足的临床需求方面取得了重要进展,有望为患者带来新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10